The treatment of Merkel cell carcinoma with immune checkpoint inhibitors: implications for patients with rheumatoid arthritis
| Autor: | Sven Perner, Susanne Schinke, Tobias Kisch, Detlef Zillikens, Gina Klee, Ewan A. Langan, Christiane Kümpers, Patrick Terheyden |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
PD-L1
Oncology medicine.medical_specialty Cell cycle checkpoint Concise Report medicine.medical_treatment Avelumab Merkel cell carcinoma Rheumatology Internal medicine PD-1 medicine immunosuppression biology business.industry Cancer Immunosuppression medicine.disease Immune checkpoint biology.protein immune checkpoint inhibition Skin cancer AcademicSubjects/MED00010 business medicine.drug |
| Zdroj: | Rheumatology Advances in Practice |
| ISSN: | 2514-1775 |
| DOI: | 10.1093/rap/rkab037 |
| Popis: | Objectives Merkel cell carcinoma (MCC) is a rare, highly aggressive neuroendocrine skin cancer, which typically affects elderly and immunocompromised and/or immunosuppressed patients. The checkpoint inhibitor avelumab, a mAb targeting the anti-programmed cell death ligand 1 (anti-PD-L1), has revolutionized the treatment of metastatic MCC, achieving dramatic improvements in disease control and overall survival. However, checkpoint inhibitors are associated with the development of immune-related adverse events, such as exacerbation of pre-existing RA. Although most immune-related adverse events can be managed successfully with CSs, their frequent and/or long-term use runs the risk of undermining the efficacy of immune checkpoint inhibition. Methods We report two cases of MCC, in which immunosuppressive therapy for the management of RA was administered. Results Immunosuppression for (i) pre-existing and (ii) immune checkpoint inhibitor-exacerbated RA was associated with progression of metastatic MCC. Conclusion Any decision to initiate immunosuppressive treatment for RA in patients receiving immune checkpoint inhibitor therapy should include careful consideration of the risk of potentially fatal cancer progression and be taken after consultation with the patient’s oncologist and rheumatologist. When the immunosuppressive treatment is required, it should be administered for as short a time as possible and under strict clinical and radiological surveillance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|